Cytosorbents Corporation

Valuation Analysis

About the Company

Cytosorbents Corporation en bref

Cytosorbents Corporation (CTSO) is currently trading at 0,38 € with a market capitalization of 24 M €. The 52-week range spans from 0,32 € to 1,21 €; the current price is 68.3% below the yearly high. Year-over-year revenue growth stands at +1.6%.

💰 Dividende

Cytosorbents Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

2 analystes évaluent Cytosorbents Corporation (CTSO) au consensus : None. L'objectif de cours moyen est de 2,51 €, soit un potentiel de +555.94% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 0,65 € à 4,36 €.

Cytosorbents Corporation : la thèse d'investissement en détail

Cytosorbents Corporation (CTSO) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 71%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

Le scénario baissier

Revenue growth has slowed to just 1.6%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. The debt-to-equity ratio of 1334.37% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.

À surveiller

• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 555.94% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Cytosorbents Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.